Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.600
+0.050 (3.23%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Acrivon Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 50 | 187 | 109 | 241 | - | - |
| Market Cap Growth | -70.73% | 71.66% | -54.61% | - | - | - |
| Enterprise Value | -76 | 4 | -28 | 291 | - | - |
| Last Close Price | 1.60 | 6.02 | 4.92 | 11.52 | - | - |
| PB Ratio | 0.39 | 1.06 | 0.90 | 1.41 | - | - |
| P/TBV Ratio | 0.39 | 1.06 | 0.90 | 1.41 | - | - |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.04 | 0.03 | 0.06 | 0.04 |
| Net Debt / Equity Ratio | -0.98 | -0.99 | -1.01 | -0.72 | -0.95 | -0.97 |
| Net Debt / EBITDA Ratio | 1.44 | 1.99 | 1.85 | 3.80 | 5.82 | 0.48 |
| Net Debt / FCF Ratio | 1.86 | 2.57 | 2.80 | 3.80 | 6.61 | 0.54 |
| Quick Ratio | 8.68 | 10.43 | 9.58 | 19.61 | 34.18 | 2.58 |
| Current Ratio | 8.75 | 10.55 | 9.75 | 20.27 | 34.46 | 2.80 |
| Return on Equity (ROE) | -50.23% | -54.07% | -41.41% | -23.16% | -32.40% | - |
| Return on Assets (ROA) | -30.89% | -33.30% | -26.25% | -14.18% | -18.60% | - |
| Return on Capital Employed (ROCE) | -68.20% | -49.70% | -53.70% | -18.70% | -15.60% | -201.50% |
| Earnings Yield | -161.92% | -42.98% | -55.30% | -12.95% | - | - |
| FCF Yield | -134.81% | -36.51% | -40.23% | -13.42% | - | - |
| Buyback Yield / Dilution | -28.87% | -53.05% | -435.63% | -136.43% | -21.70% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.